Biopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biomedtracker.
Key Takeaways
-
Continuing a multi-year trend of hectic dealmaking in the cancer antibody-drug conjugate space, five alliances centered on ADC candidates and R&D were announced this summer
ADCs have been a significant driver of biopharma dealmaking for several years now. Two of 2023’s four largest M&A transactions were big pharma buyouts of ADC specialists – Pfizer Inc.’s $43bn acquisition of Seagen Inc. that March, followed by AbbVie Inc.’s $10.1bn takeout of ImmunoGen, Inc. in November. (Also see "The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger" - Scrip, 15 January, 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?